 TG Therapeutics Inc NASDAQ: TGTX is trading lower Tuesday after the company reported the U.S. Food and Drug Administration plans to host a meeting of the Oncologic Drugs Advisory Committee in connection with its review of the pending Biologics License Applicationsupplemental New Drug Application for the combination of ublituximab and UKONIQ. The combination of ublituximab and UKONIQ is used for the treatment of adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. 